Skip to content
Review Open access

Host systemic metabolism and cancer metabolic vulnerabilities: mechanisms and therapeutic opportunities

Jul 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 111 references
Medicine

TL;DR

The thesis that metabolic plasticity—the capacity of cancer cells to dynamically switch between and co-opt multiple metabolic programs—is the primary driver of tumour progression, immune evasion, and resistance to therapy is upheld.

Abstract

Background Central molecular mediators—including hypoxia-inducible factors (HIF-1α/HIF-2α), MYC, wild-type and mutant p53, NF-κB, STAT3, SREBPs, NRF2, and KRAS—orchestrate these pathways by linking nutrient availability to oncogenic signalling, epigenetic reprogramming, and immune-metabolic crosstalk within the tumour microenvironment. Key metabolic enzymes including HK2, PKM2, LDH-A, IDH1/2, GLS1, and FASN serve as direct effectors and therapeutic targets. Mitochondrial dynamics—biogenesis (PGC-1α), fission (DRP1), fusion (MFN1/2, OPA1), and mitophagy (PINK1-Parkin)—constitute a critical regulatory layer. The bidirectional epigenetic-metabolic axis, mediated by acetyl-CoA, SAM, α-ketoglutarate, 2-hydroxyglutarate, and lysine lactylation, amplifies oncogenic transcriptional programs and locks cells into malignant states. Central to this review is the thesis that metabolic plasticity—the capacity of cancer cells to dynamically switch between and co-opt multiple metabolic programs—is the primary driver of tumour progression, immune evasion, and resistance to therapy. Understanding and targeting this plasticity represents the central translational challenge of cancer metabolic oncology. Methods A comprehensive narrative literature review was conducted across PubMed, Scopus, and Web of Science (2015–2025) using terms including metabolic reprogramming, Warburg effect, oncometabolites, mitochondrial dynamics, epigenetic metabolism, immunometabolism, and metabolic therapeutics. Peer-reviewed primary research and comprehensive reviews were evaluated. Limitations include restriction to English-language literature (2015–2025), potential publication bias toward high-impact journals, and the rapidly evolving nature of the field. Conclusion Metabolic reprogramming is governed by an interconnected network of transcription factors, signalling cascades, epigenetic regulators, mitochondrial dynamics, and TME-immune crosstalk. FDA-validated targets include IDH1/2 (ivosidenib, enasidenib, vorasidenib—August 2024), HIF-2α (belzutifan), and mTOR (everolimus). An expanding clinical pipeline encompasses GLS1, MCT1, OXPHOS Complex I, FASN, and metabolic immune checkpoints. Future advances require single-cell/spatial metabolomics, AI-driven patient stratification, and rational combination strategies that preempt adaptive metabolic escape. Future advances require AI-driven genome-scale metabolic modelling for patient stratification, single-cell and spatial metabolomics to resolve intra-tumoral metabolic heterogeneity, and rational combination strategies targeting multiple metabolic nodes simultaneously to preempt adaptive resistance. Integration of circadian pharmacology, host metabolic comorbidity management (obesity, diabetes, gut microbiome modulation), and TME metabolic normalisation into cancer treatment frameworks will drive the next generation of precision metabolic oncology.

Read PDF

Similar papers

Review Open access Aug 2026

Metabolism in Tumor: Mechanisms and Therapeutic Perspectives

Tumor metabolic reprogramming now extends far beyond the Warburg effect, spanning glycolysis, mitochondrial oxidative phosphorylation (OXPHOS), de novo lipogenesis, cholesterol biosynthesis, and fatty acid oxidation. This network is shaped by cell‐intrinsic regulatory layers—transcriptional programs, histone lactylatio...

Jia-Chen Cheng, Yi-Xuan Hu, Xiang-Chun Huang et al. · 0 citations
Review Open access Sep 2026

Lactylation in liver fibrosis: from molecular mechanisms to targeted therapeutic strategies

Metabolic reprogramming and epigenetic remodeling of hepatic stellate cells (HSCs) represent central driving events in liver fibrosis. Lactylation, a lactate-mediated post-translational modification (PTM), is proposed to converge on histone H3 lysine 18 lactylation (H3K18La) through the HK2-KAT8 positive feedback loop,...

Zhi-Wei Dong, Fei-Bo Xu, Mei Ye et al. · 0 citations
Review Aug 2026

Targeting metabolic reprogramming in cancer: Past, present, and future.

Cancer cells undergo profound metabolic reprogramming to sustain uncontrolled proliferation within a nutrient-limited and often hypoxic tumor microenvironment (TME). Metabolic rewiring is an active driver of oncogenesis, immune evasion, epigenetic remodeling, and therapy resistance. Over the past century, our understan...

Niti Kumari, Surendra K. Shukla, Ravi Thakur · 0 citations
Review Sep 2026

Metabolic and epigenetic plasticity of tumor-associated macrophages shapes immunosuppressive outputs and immune checkpoint response.

A context-dependent state-transition model is proposed in which pressures are decoded by interconnected nutrient- and stress-sensing pathways, integrated through mitochondrial bioenergetic and redox adaptation, and translated by metabolite-dependent chromatin remodeling into persistent TAM functional programs that cons...

Jing-Hao Pan, Bo-Yang Li, Lucy Yue Lau et al. · 0 citations
Review Open access Sep 2026

Metabolic Reprogramming Of Macrophages In Breast Cancer: Mechanisms And Therapeutic Implications.

In summary, in-depth elucidation of the molecular mechanisms underlying macrophage metabolic reprogramming and their metabolic crosstalk with breast cancer cells will provide new insights and novel therapeutic targets for the precise immunometabolic therapy of breast cancer.

Jiao-Yu Zhang, Rui Yang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.